



**Disclosure of Insider Information pursuant to Section 17 (1) 1 of the Regulation (EU)
No. 596/2014 on Market Abuse, as amended
(Market Abuse Regulation – MAR)**

***Dermapharm Holding SE signs cooperation and delivery
agreement with BioNTech SE***

Grünwald, September 10, 2020 – Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) and BioNTech SE, Mainz, Germany, have agreed that their production subsidiaries will cooperate on producing a COVID-19 vaccine. The production capacities at Dermapharm will be available to the cooperation partners BioNTech SE and Pfizer Inc. already when production of the vaccine begins.

>End of the ad hoc announcement<

Contacts

Investor Relations &
Corporate Communications
Britta Hamberger
Phone: +49 (0)89 – 64186-233
Fax: +49 (0)89 – 64186-165
e-mail: ir@dermapharm.com

cometis AG
Claudius Krause
Phone: +49 (0)611 – 205855-28
Fax: +49 (0)611 – 205855-66
e-mail: ir@dermapharm.com